COLCHICINE COMPOSITIONS AND METHODS

• US 20100105780A1
• Filed: 01/14/2010
• Published: 04/29/2010
• Est. Priority Date: 10/05/2007
• Status: Active Grant

• Current Assignee: Takeda Pharmaceutical Company Limited
• Original Assignee: Mutual Pharmaceutical Company (Takeda Pharmaceutical Company Limited)
• Inventors: DAVIS, Matthew W.
• Granted Patent: US 7,981,938 B2
• Time in Patent Office: Days
• US Class Current: 514/625
• CPC Class Codes: A61K 31/16 Amides, e.g. hydroxamic acids
• CPC Class Codes: A61K 31/165 having aromatic rings, e.g. colchicine, atenolol, progabide
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/06 Antigout agents, e.g. antihyperuricemic or uricosuric agents
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed.

Claims

1. A method of treating a gout flare in a patient undergoing prophylactic treatment of gout flares, comprising

administering a colchicine dosing regimen to a patient having a gout flare while undergoing prophylactic treatment of gout flares,

wherein the prophylactic treatment is 0.6 mgA or 1.2 mgA oral colchicine daily, and

the colchicine dosing regimen consists of 1.2 mgA oral colchicine at the onset of the acute gout flare, followed by 0.6 mgA oral colchicine about one hour later, and after waiting 12 hrs continuing the prophylactic treatment.